AU StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

ORTHOCELL LTD

1.255

+0.0201.62%

Volume:1.26M

Turnover:1.61M

Market Cap:301.13M

PE:-78.74

High:1.335

Open:1.230

Low:1.210

Close:1.235

Loading ...

Overview Company News Filings

Here's Why We're Not Too Worried About Orthocell's (ASX:OCC) Cash Burn Situation

Simply Wall St.

Transportation costs the biggest hurdle in interprovincial trade: survey

Investors bid Orthocell (ASX:OCC) up AU$53m despite increasing losses YoY, taking one-year return to 347%

Simply Wall St.

Orthocell Submits Canada License Application for Nerve Repair Product

MT Newswires Live

BRIEF-Orthocell Submits Canada Regulatory Application To Commence Sales Of Remplir

Orthocell Ltd - Submits Canada Regulatory Application to Commence Sales of Remplir

THOMSON REUTERS

BUZZ-Australia's Orthocell climbs to 2-week high as co floats expansion plans

BRIEF-Orthocell Says Market Expansion Of Remplir Will Be Accelerated

Orthocell Accelerates Global Expansion for Remplir, Shares Rally 14%

MT Newswires Live

Orthocell Ltd - Market Expansion of Remplir Will Be Accelerated Ahead of US FDA Clearance Expected in March/April 2025

THOMSON REUTERS

Orthocell Poised to Meet Fiscal 2025 Revenue Estimate; Euroz Hartley Says

MT Newswires Live

ASX Market Update: Inflation higher than expected as miners bounce back | January 8, 2025

The Market Herald

Orthocell Logs Another Record Revenue in December 2024 Quarter; Shares Up 5%

MT Newswires Live

Those who invested in Orthocell (ASX:OCC) a year ago are up 235%

Simply Wall St.

Orthocell Files Premarket Application With US FDA for Nerve Repair Device; Shares Down 5%

MT Newswires Live

Orthocell Ltd-US FDA Application Submitted for Remplir as US Launch Nears

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/OCC.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"OCC.AU"},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"OCC.AU\",,,,,undefined,":{"symbol":"OCC.AU","market":"AU","secType":"STK","nameCN":"ORTHOCELL LTD","latestPrice":1.255,"timestamp":1741583520000,"preClose":1.235,"halted":0,"volume":1261626,"delay":0,"changeRate":0.016194,"change":0.02,"floatShares":189223994,"shares":239947475,"eps":-0.015939,"lyrEps":-0.035547,"pbRate":15.33,"amount":1611957,"amplitude":0.101215,"volumeRatio":0.922447,"dividePrice":0,"prevYearClose":1.355,"fiveDayClose":1.315,"twentyDayClose":1.68},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"OCC.AU\",,,,,undefined,":{"symbol":"OCC.AU","floatShares":189223994,"roa":"-20.32%","roe":"-29.77%","lyrEps":-0.035547,"volumeRatio":0.922447,"shares":239947475,"dividePrice":0,"high":1.335,"amplitude":0.101215,"preClose":1.235,"low":1.21,"week52Low":0.35,"pbRate":"15.33","psRate":"47.69","week52High":1.79,"institutionHeld":0,"latestPrice":1.255,"committee":-0.667497,"eps":-0.015939,"divideRate":0,"volume":1261626,"delay":0,"ttmEps":-0.015939,"open":1.23,"prevYearClose":1.355,"prevWeekClose":1.235,"prevMonthClose":1.295,"prevQuarterClose":1.355,"fiveDayClose":1.315,"twentyDayClose":1.68,"sixtyDayClose":0.96},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/OCC.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"OCC.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"OCC.AU\",pageSize:16,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2514041834","title":"Here's Why We're Not Too Worried About Orthocell's (ASX:OCC) Cash Burn Situation","url":"https://stock-news.laohu8.com/highlight/detail?id=2514041834","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514041834?lang=en_us&edition=fundamental","pubTime":"2025-02-26 04:36","pubTimestamp":1740515815,"startTime":"0","endTime":"0","summary":"There's no doubt that money can be made by owning shares of unprofitable businesses. By way of example, Orthocell  has seen its share price rise 196% over the last year, delighting many shareholders. But the harsh reality is that very many loss making companies burn through all their cash and go bankrupt.So notwithstanding the buoyant share price, we think it's well worth asking whether Orthocell's cash burn is too risky. In this article, we define cash burn as its annual  free cash flow, which is the amount of money a company spends each year to fund its growth. First, we'll determine its cash runway by comparing its cash burn with its cash reserves.As you can probably tell by now, we're not too worried about Orthocell's cash burn. For example, we think its cash runway suggests that the company is on a good path. While its increasing cash burn wasn't great, the other factors mentioned in this article more than make up for","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/heres-why-were-not-too-203655065.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["OCC.AU","BK7067","BK7508","OCC","BK4020"],"gpt_icon":0},{"id":"2512092594","title":"Transportation costs the biggest hurdle in interprovincial trade: survey","url":"https://stock-news.laohu8.com/highlight/detail?id=2512092594","media":"Bloomberg","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512092594?lang=en_us&edition=fundamental","pubTime":"2025-02-16 07:12","pubTimestamp":1739661145,"startTime":"0","endTime":"0","summary":"A national survey suggests transportation costs are the most common hindrance to interprovincial trade for businesses both selling and purchasing goods and services.","market":"hk","thumbnail":"https://cloudfront-us-east-1.images.arcpublishing.com/bellmediainc/WYKGOL7R5BC47JMLLWP4ERAP7A.jpg","type":0,"news_type":0,"thumbnails":["https://cloudfront-us-east-1.images.arcpublishing.com/bellmediainc/WYKGOL7R5BC47JMLLWP4ERAP7A.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.bnnbloomberg.ca/business/politics/2025/02/15/transportation-costs-the-biggest-hurdle-in-interprovincial-trade-survey/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"bnn_bloomberg_highlight","symbols":["BK7067","BK4020","BK7508","OCC","OCC.AU"],"gpt_icon":0},{"id":"2509734013","title":"Investors bid Orthocell (ASX:OCC) up AU$53m despite increasing losses YoY, taking one-year return to 347%","url":"https://stock-news.laohu8.com/highlight/detail?id=2509734013","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509734013?lang=en_us&edition=fundamental","pubTime":"2025-02-07 04:00","pubTimestamp":1738872045,"startTime":"0","endTime":"0","summary":"For many, the main point of investing in the stock market is to achieve spectacular returns. While not every stock...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-occ/orthocell-shares/news/investors-bid-orthocell-asxocc-up-au53m-despite-increasing-l","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ISBC","BK4211","BK4020","BK7508","OCC.AU","BK7067","OCC"],"gpt_icon":0},{"id":"2508154166","title":"Orthocell Submits Canada License Application for Nerve Repair Product","url":"https://stock-news.laohu8.com/highlight/detail?id=2508154166","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508154166?lang=en_us&edition=fundamental","pubTime":"2025-02-03 07:46","pubTimestamp":1738539985,"startTime":"0","endTime":"0","summary":"Orthocell  submitted a medical device license application in Canada for its nerve repair product Remplir, according to a Monday Australian bourse filing.The company expects the product to be approved in Canada in the second half of 2025.It is planning to submit regulatory applications in Thailand in the March quarter, in the UK and the European Union in the September quarter, and in Brazil in the December quarter.It is also evaluating Southeast Asian and Latin American markets.It added that it expects US Food and Drug Administration approval in March or early April. Preparations for a market launch in the US are underway.The company's shares fell past 3% in recent Monday trade.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7508","OCC.AU","BK7067"],"gpt_icon":0},{"id":"2508159463","title":"BRIEF-Orthocell Submits Canada Regulatory Application To Commence Sales Of Remplir","url":"https://stock-news.laohu8.com/highlight/detail?id=2508159463","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508159463?lang=en_us&edition=fundamental","pubTime":"2025-02-03 06:33","pubTimestamp":1738535597,"startTime":"0","endTime":"0","summary":"BRIEF-Orthocell Submits Canada Regulatory Application To Commence Sales Of RemplirFeb 3 (Reuters) - Orthocell Ltd OCC.AX:SUBMITS CANADA REGULATORY APPLICATION TO COMMENCE SALES OF REMPLIRFurther company coverage: OCC.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250202:nFWN3OS06F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OCC.AU"],"gpt_icon":0},{"id":"2508315673","title":"Orthocell Ltd - Submits Canada Regulatory Application to Commence Sales of Remplir","url":"https://stock-news.laohu8.com/highlight/detail?id=2508315673","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508315673?lang=en_us&edition=fundamental","pubTime":"2025-02-03 06:01","pubTimestamp":1738533685,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250202:nFWN3OS06F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","OCC.AU","BK7508"],"gpt_icon":0},{"id":"2505766845","title":"BUZZ-Australia's Orthocell climbs to 2-week high as co floats expansion plans","url":"https://stock-news.laohu8.com/highlight/detail?id=2505766845","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505766845?lang=en_us&edition=fundamental","pubTime":"2025-01-22 12:49","pubTimestamp":1737521354,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Orthocell climbs to 2-week high as co floats expansion plans** Shares of Orthocell OCC.AX rise 15.4% to A$1.500, their highest levels since Jan 6** The regenerative medicine firm says that it plans to enter key markets such as Canada and Thailand, among others, in CY2025** Orthocell recently submitted its USFDA regulatory application for the clearance to distribute its nerve drug Remplir in the $1.6 bln  U.S. market commercially** Co expects approval in March/April 2025** About 3.4 mln shares trade hands, 1.9 times the 30-day average of 1.8 mln** Stock rose 230.5% in 2024  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250122:nL3N3OI0BN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OCC.AU","BK7067","BK7508"],"gpt_icon":0},{"id":"2505753628","title":"BRIEF-Orthocell Says Market Expansion Of Remplir Will Be Accelerated","url":"https://stock-news.laohu8.com/highlight/detail?id=2505753628","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505753628?lang=en_us&edition=fundamental","pubTime":"2025-01-22 09:31","pubTimestamp":1737509461,"startTime":"0","endTime":"0","summary":"BRIEF-Orthocell Says Market Expansion Of Remplir Will Be AcceleratedJan 22 (Reuters) - Orthocell Ltd OCC.AX:MARKET EXPANSION OF REMPLIR WILL BE ACCELERATED AHEAD OF US FDA CLEARANCE EXPECTED IN MARCH/","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250122:nFWN3OH1XT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","OCC.AU","BK7067"],"gpt_icon":0},{"id":"2505586757","title":"Orthocell Accelerates Global Expansion for Remplir, Shares Rally 14%","url":"https://stock-news.laohu8.com/highlight/detail?id=2505586757","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505586757?lang=en_us&edition=fundamental","pubTime":"2025-01-22 09:17","pubTimestamp":1737508624,"startTime":"0","endTime":"0","summary":"Orthocell  is set to accelerate its plans to enter several key markets in 2025, with a regulatory submission for its Remplir product for Canada expected to be lodged shortly, on the back of a third consecutive quarter of record revenue, according to a Wednesday Australian bourse filing.It plans to submit regulatory applications for the peripheral nerve reconstruction product in Thailand during the March quarter, in the European Union and UK during the September quarter, and in Brazil during the December quarter.The firm had earlier submitted its US regulatory application for clearance to commercially distribute Remplir, with approval expected in either March or April. Remplir is currently approved for sale in Australia, New Zealand, and Singapore.It said that it is progressing with preparations for its US market launch, including the recruitment of an initial sales team and distributor appointments.The firm's shares rallied 14% in early trading on Wednesday.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["OCC.AU","XAO.AU","XJO.AU","XKO.AU","BK7067","BK7508"],"gpt_icon":0},{"id":"2505978067","title":"Orthocell Ltd - Market Expansion of Remplir Will Be Accelerated Ahead of US FDA Clearance Expected in March/April 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2505978067","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505978067?lang=en_us&edition=fundamental","pubTime":"2025-01-22 05:59","pubTimestamp":1737496746,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250121:nFWN3OH1XT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","OCC.AU","BK7067"],"gpt_icon":0},{"id":"2504736439","title":"Orthocell Poised to Meet Fiscal 2025 Revenue Estimate; Euroz Hartley Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2504736439","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2504736439?lang=en_us&edition=fundamental","pubTime":"2025-01-17 08:51","pubTimestamp":1737075081,"startTime":"0","endTime":"0","summary":"Orthocell  is on track to meet Euroz Hartley's fiscal 2025 revenue forecast of AU$8.8 million, following positive second-quarter results that met expectations, according to a Wednesday note from the financial services firm.The company reported a 9% quarter-on-quarter increase in revenue to AU$2.2 million, bringing first-half revenue to AU$4.2 million, up 29% year-on-year, Euroz Hartleys said.Euroz Hartleys noted that growth was driven by product launches, including Striate+ for dental bone repair and Remplir for nerve repair.Euroz Hartley believes that the upcoming US FDA approval of Orthocell's Remplir product, expected by April, will be a key catalyst for the company's growth. Approval would allow Remplir to enter the $1.6 billion US nerve repair market, and see a potential increase in the company's share price, it added.Euroz Hartleys maintained the company's hold rating and its price target of AU$0.97.Orthocell's shares slipped almost 1% in recent Friday trade.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["OCC.AU"],"gpt_icon":1},{"id":"2501988077","title":"ASX Market Update: Inflation higher than expected as miners bounce back | January 8, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2501988077","media":"The Market Herald","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501988077?lang=en_us&edition=fundamental","pubTime":"2025-01-08 10:28","pubTimestamp":1736303280,"startTime":"0","endTime":"0","summary":"The ASX200 has been up 0.65% at 8,338 points in afternoon trade.Inflation edged upmore than expected, from2.1% to 2.3%. More importantly, trimmed mean inflation  came in at3.2%,still outside the RBA’s 2% to 3% target range.While consensus had shifted towards a 70% probability of a rate cut in February, some analysts don’t see this happening until later in the year.Materials has bounced back and has been the biggest winner, up 1.5%, followed by Financials, up 0.85%, and Health Care, up 0.75%.IT has lost the most ground, down 0.7%, followed by Real Estate and Telecommunication, both down 0.3%.Meeka Metalshas been up 10.5% on a breakthrough in its drilling program at St Anne’s within the Murchison Gold Project. The latest assays reveal bonanza-grade gold intersections, bolstering plans for an expanded Stage 1 open pit.Orthocell  has been up 5.6% after posting a third consecutive quarter of record revenue. The company reported a 46% increase in revenue to $2.21 million for the December ’24","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://themarketonline.com.au/asx-market-update-inflation-higher-than-expected-as-miners-bounce-back-january-8-2025-2025-01-08/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["BK7508","MEK.AU","OCC.AU","AVH.AU","BK7067","BK7104"],"gpt_icon":0},{"id":"2501750433","title":"Orthocell Logs Another Record Revenue in December 2024 Quarter; Shares Up 5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2501750433","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501750433?lang=en_us&edition=fundamental","pubTime":"2025-01-08 08:25","pubTimestamp":1736295939,"startTime":"0","endTime":"0","summary":"Orthocell's  revenue climbed 46% to AU$2.2 million in the three months to December 2024 from AU$1.5 million in the year-earlier period, according to a Wednesday filing with the Australian bourse.Revenue was up 9% from AU$2 million in the three months to September 2024, marking a third consecutive quarter of record revenue.The regenerative medicine company attributed the increase to growth in existing markets for its Striate and Remplir products, per the filing. It anticipates the US Food and Drug Administration's approval of Remplir by March or April, enabling it to unlock a $1.6 billion nerve repair market.Orthocell's shares rose past 5% in recent Wednesday trade.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["OCC.AU"],"gpt_icon":0},{"id":"2500952625","title":"Those who invested in Orthocell (ASX:OCC) a year ago are up 235%","url":"https://stock-news.laohu8.com/highlight/detail?id=2500952625","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500952625?lang=en_us&edition=fundamental","pubTime":"2025-01-01 05:42","pubTimestamp":1735681333,"startTime":"0","endTime":"0","summary":"When you buy shares in a company, there is always a risk that the price drops to zero. But when you pick a company that is really flourishing, you can make more than 100%. Take, for example Orthocell Limited . Its share price is already up an impressive 235% in the last twelve months. It's also good to see the share price up 230% over the last quarter. Looking back further, the stock price is 168% higher than it was three years ago.Let's take a look at the underlying fundamentals over the longer term, and see if they've been consistent with shareholders returns.Given that Orthocell didn't make a profit in the last twelve months, we'll focus on revenue growth to form a quick view of its business development. When a company doesn't make profits, we'd generally hope to see good revenue growth. That's because it's hard to be confident a company will be sustainable if revenue growth is negligible, and it never makes a profit.Please note, the market returns quoted in this article reflect the","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/those-invested-orthocell-asx-occ-214213196.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["OCC","BK4020","BK7508","OCC.AU","BK7067"],"gpt_icon":0},{"id":"2492160494","title":"Orthocell Files Premarket Application With US FDA for Nerve Repair Device; Shares Down 5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2492160494","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492160494?lang=en_us&edition=fundamental","pubTime":"2024-12-19 09:32","pubTimestamp":1734571949,"startTime":"0","endTime":"0","summary":"Orthocell  submitted a 510 application with the US Food and Drug Administration to sell its Remplir nerve repair device in the US market, according to a Thursday filing with the Australian bourse.The submission is based on a regulatory study of Remplir, which met all the endpoints and provided key data to support the application, the filing said.The 90-calendar day review process is expected to start between March and April 2025, with commercial distribution expected soon after, the filing said.Shares fell nearly 5% in midday trade Thursday.Price : $1.20, Change: $-0.06, Percent Change: -4.78%","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["AUD","BK4125","LU0994945656.USD","LU0345774631.USD","BK7067","LU0426412945.USD","OCC.AU","LU0426417589.USD","LU1043141123.HKD","LU2238339852.HKD","BK7508"],"gpt_icon":0},{"id":"2492322150","title":"Orthocell Ltd-US FDA Application Submitted for Remplir as US Launch Nears","url":"https://stock-news.laohu8.com/highlight/detail?id=2492322150","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492322150?lang=en_us&edition=fundamental","pubTime":"2024-12-19 06:02","pubTimestamp":1734559347,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241218:nTUE6XLNCX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["OCC.AU","BK7508","BK7067"],"gpt_icon":0}],"pageSize":16,"totalPage":4,"pageCount":1,"totalSize":52}]}}